Urgent Guidance for Navigating and Circumventing the QTc-Prolonging and Torsadogenic Potential of Possible Pharmacotherapies for Coronavirus Disease 19 (COVID-19)

Mayo Clinic Proceedings

Volumn 95, Issue 6, 2020, Pages 1213-1221

  Giudicessi, John R ^a   Noseworthy, Peter A ^a   Friedman, Paul A ^a   Ackerman, Michael J ^a,b  

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN CONVERTING ENZYME 2; AZITHROMYCIN; CHLOROQUINE; CYTOKINE; HYDROXYCHLOROQUINE; LOPINAVIR PLUS RITONAVIR; POTASSIUM CHANNEL HERG; REMDESIVIR; SARILUMAB; ANTIINFECTIVE AGENT; LOPINAVIR; LOPINAVIR-RITONAVIR DRUG COMBINATION; RITONAVIR;

ARTICLE; CHANNEL GATING; CORONAVIRUS DISEASE 2019; CYTOKINE STORM; DRUG REPOSITIONING; DRUG SAFETY; ELECTROCARDIOGRAPHY MONITORING; HEALTH CARE PERSONNEL; HEART VENTRICLE ARRHYTHMIA; HUMAN; INHIBITION KINETICS; MOBILE APPLICATION; PANDEMIC; POST EXPOSURE PROPHYLAXIS; QT PROLONGATION; RESOURCE MANAGEMENT; RISK REDUCTION; SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2; SUDDEN CARDIAC DEATH; TORSADE DES POINTES; VIRUS ENTRY; BETACORONAVIRUS; CORONAVIRUS INFECTION; DRUG COMBINATION; DRUG EFFECT; DRUG MONITORING; ELECTROCARDIOGRAPHY; ETHICS; ISOLATION AND PURIFICATION; LONG QT SYNDROME; MORTALITY; PRACTICE GUIDELINE; PROCEDURES; RISK ASSESSMENT; VIRUS PNEUMONIA;

ANTI-INFECTIVE AGENTS; BETACORONAVIRUS; CORONAVIRUS INFECTIONS; DEATH, SUDDEN, CARDIAC; DRUG COMBINATIONS; DRUG MONITORING; DRUG REPOSITIONING; ELECTROCARDIOGRAPHY; HUMANS; HYDROXYCHLOROQUINE; LONG QT SYNDROME; LOPINAVIR; PANDEMICS; PNEUMONIA, VIRAL; RISK ADJUSTMENT; RITONAVIR; TORSADES DE POINTES;

EID: 85083010319     PISSN: 00256196     EISSN: 19425546     Source Type: Journal    
DOI: 10.1016/j.mayocp.2020.03.024     Document Type: Article

References (26)

1. Huang, C., Wang, Y., Li, X., et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China [published correction appears in Lancet. 2020;395(10223):496]. Lancet 395:10223 (2020), 497–506.
2. Shah, A., Kashyap, R., Tosh, P., Sampathkumar, P., O'Horo, J.C., Guide to understanding the 2019 novel coronavirus [published online ahead of print February 28, 2020]. Mayo Clin Proc https://doi.org/10.1016/j.mayocp.2020.02.003.
3. Wang, M., Cao, R., Zhang, L., et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 30:3 (2020), 269–271.
4. Yao, X., Ye, F., Zhang, M., et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [published online ahead of print March 9, 2020]. Clin Infect Dis https://doi.org/10.1093/cid/ciaa237.
5. Gautret, P., Lagier, J.C., Parola, P., et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: preliminary results of an open-label non-randomized clinical trial. medRxiv, 03, 2020, 10.1101/2020.03.16.20037135.
6. Colson, P., Rolain, J.M., Lagier, J.C., Brouqui, P., Raoult, D., Chloroquine and hydroxychloroquine as available weapons to fight COVID-19 [published online ahead of print March 4, 2020]. Int J Antimicrob Agents https://doi.org/10.1016/j.ijantimicag.2020.105932.
7. Savarino, A., Boelaert, J.R., Cassone, A., Majori, G., Cauda, R., Effects of chloroquine on viral infections: an old drug against today's diseases?. Lancet Infect Dis 3:11 (2003), 722–727.
8. Vincent, M.J., Bergeron, E., Benjannet, S., et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J, 2, 2005, 69.
9. Haugaa, K.H., Bos, J.M., Tarrell, R.F., Morlan, B.W., Caraballo, P.J., Ackerman, M.J., Institution-wide QT alert system identifies patients with a high risk of mortality. Mayo Clin Proc 88:4 (2013), 315–325.
10. Giudicessi, J.R., Ackerman, M.J., Camilleri, M., Cardiovascular safety of prokinetic agents: a focus on drug-induced arrhythmias. Neurogastroenterol Motil, 30(6), 2018, e13302.
11. Garabelli, P., Stavrakis, S., Albert, M., et al. Comparison of QT interval readings in normal sinus rhythm between a smartphone heart monitor and a 12-lead ECG for healthy volunteers and inpatients receiving sotalol or dofetilide. J Cardiovasc Electrophysiol 27:7 (2016), 827–832.
12. Sharma, S., Drezner, J.A., Baggish, A., et al. International recommendations for electrocardiographic interpretation in athletes. Eur Heart J 39:16 (2018), 1466–1480.
13. Vink, A.S., Neumann, B., Lieve, K.V.V., et al. Determination and interpretation of the QT interval. Circulation 138:21 (2018), 2345–2358.
14. Goldenberg, I., Moss, A.J., Peterson, D.R., et al. Risk factors for aborted cardiac arrest and sudden cardiac death in children with the congenital long-QT syndrome. Circulation 117:17 (2008), 2184–2191.
15. Hobbs, J.B., Peterson, D.R., Moss, A.J., et al. Risk of aborted cardiac arrest or sudden cardiac death during adolescence in the long-QT syndrome. JAMA 296:10 (2006), 1249–1254.
16. Sauer, A.J., Moss, A.J., McNitt, S., et al. Long QT syndrome in adults. J Am Coll Cardiol 49:3 (2007), 329–337.
17. Roden, D.M., Long QT syndrome: reduced repolarization reserve and the genetic link. J Intern Med 259:1 (2006), 59–69.
18. Giudicessi, J.R., Noseworthy, P.A., Ackerman, M.J., The QT interval. Circulation 139:24 (2019), 2711–2713.
19. Traebert, M., Dumotier, B., Meister, L., Hoffmann, P., Dominguez-Estevez, M., Suter, W., Inhibition of hERG K+ currents by antimalarial drugs in stably transfected HEK293 cells. Eur J Pharmacol 484:1 (2004), 41–48.
20. Stas, P., Faes, D., Noyens, P., Conduction disorder and QT prolongation secondary to long-term treatment with chloroquine. Int J Cardiol 127:2 (2008), e80–e82.
21. Chen, C.Y., Wang, F.L., Lin, C.C., Chronic hydroxychloroquine use associated with QT prolongation and refractory ventricular arrhythmia. Clin Toxicol (Phila) 44:2 (2006), 173–175.
22. Chen, F., Chan, K.H., Jiang, Y., et al. In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds. J Clin Virol 31:1 (2004), 69–75.
23. Cao, B., Wang, Y., Wen, D., et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19 [published online ahead of print March 18, 2020]. N Engl J Med https://doi.org/10.1056/NEJMoa2001282.
24. Soliman, E.Z., Lundgren, J.D., Roediger, M.P., et al. Boosted protease inhibitors and the electrocardiographic measures of QT and PR durations. AIDS 25:3 (2011), 367–377.
25. Giudicessi, J.R., Ackerman, M.J., Azithromycin and risk of sudden cardiac death: guilty as charged or falsely accused?. Cleve Clin J Med 80:9 (2013), 539–544.
26. Arellano-Rodrigo, E., García, A., Mont, L., Roqué, M., Torsade de pointes and cardiorespiratory arrest induced by azithromycin in a patient with congenital long QT syndrome [in Spanish]. Med Clin (Barc) 117:3 (2001), 118–119.